5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists. 2002

Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
Laboratory for Medicinal Chemistry (FFW), Ghent University, Harelbekestraat 72, 9000 Gent, Belgium. serge.vancalenbergh@rug.ac.be

The synthesis and structure-activity relationship of N(6)-cyclopentyl-3'-substituted-xylofuranosyladenosine analogues with respect to various adenosine receptors were explored in order to identify selective and potent antagonists and inverse agonists for the adenosine A(1) receptor. In particular, the effects of removal of the 5'-OH group and introduction of selected substituents at the 3'-NH(2) position of 9-(3-amino-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine were probed. A solid phase-assisted synthetic approach was used to optimize the 3'-amide functionality. In view of the general concern of the presence of a 5'-OH moiety with regard to cellular toxicity, the present study describes 5'-deoxy compounds with reasonable affinity for the human adenosine A(1) receptor. Interestingly, this study shows that optimization of the 3'-"up" amide substituent can substantially compensate for the drop in affinity for the adenosine A(1) receptor, which is generally observed upon removal of the 5'-OH group. The fact that for several 3'-amido-substituted (5'-deoxy)-N(6)-cyclopentyladenosine derivatives, guanosine 5'-triphosphate-induced shifts in K(i) values were significantly lower than 1 implies that these analogues behave as inverse agonists. This is further supported by their 1,3-dipropyl-8-cyclopentylxanthine-like capacity to increase forskolin-induced adenosine cyclic 3',5'-phosphate production.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D003839 Deoxyadenosines Adenosine molecules which can be substituted in any position, but are lacking one hydroxyl group in the ribose part of the molecule. Adenine Deoxyribonucleosides,Adenylyldeoxyribonucleosides,Deoxyadenosine Derivatives,Deoxyribonucleosides, Adenine,Derivatives, Deoxyadenosine
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO

Related Publications

Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
March 1970, Journal of pharmaceutical sciences,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
January 1965, Journal of pharmaceutical sciences,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
July 1984, The Journal of biological chemistry,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
January 1967, Journal of medicinal chemistry,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
January 2023, International review of neurobiology,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
November 1989, The Biochemical journal,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
November 1977, The Journal of organic chemistry,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
May 1988, Journal of chromatography,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
July 1985, Carbohydrate research,
Serge Van Calenbergh, and Andreas Link, and Shelly Fujikawa, and Rianne A F de Ligt, and Veerle Vanheusden, and Abolfasl Golisade, and Norbert M Blaton, and Jef Rozenski, and Adriaan P IJzerman, and Piet Herdewijn
July 1985, Carbohydrate research,
Copied contents to your clipboard!